PierianDx and Pillar Biosciences Announce Partnership to Support Precision Cancer Care
14.10.2020 15:00:00 EEST | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT®, is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com.
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®– and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
Contact information
Media contact for PierianDx:
Garreth Hippe
info@pieriandx.com
Media contact for Pillar Biosciences:
William Wright
info@pillar-biosciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Awards $351,000 in Scholarships to 85 Students Shaping the Future of Optics and Photonics28.5.2026 21:15:00 EEST | Press release
SPIE, the international society of optics and photonics, announced awarding $351,000 in scholarships that will provide support to 85 SPIE Student Members studying optics, photonics, or a related field. The scholarships range from $3,000 to $11,000 and awardees are selected by the SPIE Scholarship Committee from a roster of applicants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528142502/en/ “I am deeply passionate about advancing the inclusion of women and other underrepresented groups in the fields of optics and photonics, which makes it especially meaningful to be recognized as a recipient,” said Alana Gonzales, who received a $10,000 Women in Optics Scholarship. “Being able to apply this scholarship toward tuition, fees, and essential academic expenses such as books and electronics will both ease the financial burden of the final year of my PhD program and help position me for continued success.” “Congratulations t
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 15:30:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, tolerability, and clinical effects of RLS-1496 1% cream in adult patients with AK on the forearms. RLS-1496 is the first selective glutathione peroxidase 4 (GPX4) modulator to be studied in human trials, and the first targeting cellular rejuvenation as a new therapeutic pathway in a novel category called Adaptive SenoTherapeutics. Interim data from the study were presented at the RBC Capital Markets Global Healthcare Conference in New York City on May 19, 2026. Preliminary RLS-1496 Actinic Keratosis Trial Results The Phase 1b/2a
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark the eighth consecutive year of wins for ExaGrid at the Networ
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 15:00:00 EEST | Press release
Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM to trace a five-step dependency chain across the real estate, and accuracy collapses. The answer arrives with confidence. The architect inherits the consequ
European DataWarehouse Launches DealDox ® , a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 15:00:00 EEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom